Clinical calculator summary
Original 1998 Hasenclever IPS-7
Clinical calculator summary
Original 1998 Hasenclever IPS-7
A seven-factor pretreatment prognostic score for locally defined advanced Hodgkin lymphoma.
Evidence-based context for fast calculator use
- Purpose:
- Reproduce the original adverse-factor total and matched historical five-year freedom-from-progression row.
- Population:
- Patients with locally defined advanced Hodgkin lymphoma assessed at baseline in the historical derivation setting.
- Factors:
- Age, Sex, Stage IV, Albumin, Hemoglobin, WBC, Absolute or percentage lymphocytes
- Reference:
- Hasenclever and Diehl. N Engl J Med. 1998;339:1506-1514.
IPS (Hodgkin Lymphoma)
One point at age 45 or older. Ages outside the source cohort range of 15-65 are retained with a warning.
Must be greater than 0. One point below 4.0 g/dL.
Must be greater than 0. One point below 10.5 g/dL.
Must be greater than 0. One point at 15,000/mm³ or higher.
At least one pretreatment lymphocyte measurement is required; choose both only when both values are available.
Clinical Context & Background
Original 1998 IPS-7 = age >=45 + male sex + stage IV + albumin <4.0 g/dL + hemoglobin <10.5 g/dL + WBC >=15,000/mm3 + (absolute lymphocytes <600/mm3 or lymphocytes <8% of WBC).Reference Data
| IPS-7 Score | Historical 5-Year Freedom From Progression |
|---|---|
| 0 | 84% |
| 1 | 77% |
| 2 | 67% |
| 3 | 60% |
| 4 | 51% |
| >=5 | 42% |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Use at baseline for a patient with locally defined advanced Hodgkin lymphoma resembling the original cohort.
- Enter unrounded pretreatment clinical and laboratory values.
How To Interpret
- Add one point for each of the seven original adverse factors.
- Match totals 0, 1, 2, 3, 4, or >=5 to the corresponding historical five-year freedom-from-progression row.
What To Do Next
- Interpret the historical score with contemporary disease assessment, imaging, pathology, and multidisciplinary judgment.
- Use current disease-specific guidance for treatment decisions.
Limitations
- Not for early-stage disease, relapse, interim-PET assessment, or treatment selection.
- Historical cohort outcomes are not individualized prognoses.
- Ages outside 15-65 years were not represented in the original cohort.
Validated Population
Advanced Hodgkin lymphoma cohort treated before 1992; source ages 15-65 years.
Calculation verification history
Verified
Calculation verification history
Verified: Production browser revalidation
- Three source-backed cases passed through all visible production controls at IPS-7 scores 0, 1, and 7.
- The exact age-45 adverse-factor boundary and historical five-year freedom-from-progression rows 84%, 77%, and 42% matched the source-locked engine.
- No unexpected N/A, stale control, literal undefined/null value, or browser-console error was observed.
Case-level evidence is retained in validation/browser-revalidation/ips-hodgkin-2026-08-03.json.
: Production browser validation
- Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
- Overall browser status: failed-console. medium: Production emitted minified React error #418 during route loads/reloads used by this run.
- Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.
Case-level production evidence is retained in validation/browser-production/ips-hodgkin.json.
: Full validation test
- 512/512 source-rule, sibling-engine parity, exact threshold/source-age, strict-input, UI, trace, historical-outcome, wording, immutability, registry, and no-panel checks passed with zero score or outcome mismatches.
- This route has its own evidence and verification status; no badge was inherited from the separately tested ips-hodgkin-adult route.
: Calculation and input-contract correction
- Replaced favorable pre-scored defaults and permissive summation with raw age, semantic sex/stage, raw laboratory values, and explicit absolute/percentage lymphocyte availability.
- Normalized the route inputs into the validated shared IPS-7 engine and enforced exact keys, finite values, at least one lymphocyte measurement, and rejection of missing, extra, coercive, and nonfinite values.
- Restored the exact original thresholds and six historical five-year freedom-from-progression rows while removing unsupported treatment-selection and individualized-prognosis wording.
Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.
Frequently Asked Questions
When should IPS (Hodgkin Lymphoma) be used?
Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.
Can IPS (Hodgkin Lymphoma) determine treatment by itself?
No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.
Evidence-based oncology decision support. Verify with clinical guidelines.